Une étude randomisée de phase 3 visant à comparer la lymphadénectomie axillaire à la radiothérapie axillaire chez des sujets atteints de cancer du sein (cT1-3 N1) touchant les ganglions sentinelles après la chimiothérapie néoadjuvante
MAC.19
NCT01901094
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DU SAINT-SACREMENT
|
Sein |
Dre Christine Desbiens
Nathalie Carmichael
418-682-7511 poste 4551
|
Étude clinique prospective évaluant l’utilité et l’impact économique du score de récurrence de l’Oncotype DX chez des patientes atteintes de cancer du sein à ganglions positifs candidates à la thérapie néo-adjuvante au Québec.
NeaOnQ
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DU SAINT-SACREMENT
|
Sein |
Dre Louise Provencher
Jean-Charles Hogue
418-525-4444 poste 82424
|
(EN) RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy
BREVITY
NCT03524430
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DU SAINT-SACREMENT
|
Sein |
Dre Brigitte Poirier
Fanie Bourgault
418-525-4444 poste 82697
|
(EN) STREAMLoc- Streamlined Localization Using SCOUT® at Biopsy: An Analysis of Process Improvement, Cost Savings and Enhanced Patient Experience.
STREAMLoc
NCT04815291
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DU SAINT-SACREMENT
|
Sein |
Dre Christine Desbiens
Judith-Élise Marcoux
418-525-4444 poste 84577
|
(EN) A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH-]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy
ASCENT-07
NCT05840211
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DU SAINT-SACREMENT
|
Sein |
Dr André Blais
Fanie Bourgault
418-525-4444 poste 82697
|
(EN) A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
WO44263
NCT05894239
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DU SAINT-SACREMENT
|
Sein |
Dre Catherine Doyle
Fanie Bourgault
418-525-4444 poste 82697
|
(EN) A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
CAMBRIA-2
NCT05952557
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DU SAINT-SACREMENT
|
Sein |
Dre Julie Lemieux
Marie-Caude Lépine
418-525-4444 poste 82100
|
(EN) A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy
pionERA Breast Cancer
NCT06065748
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DU SAINT-SACREMENT
|
Sein |
Dre Julie Lemieux
Judith-Élise Marcoux
418-525-4444 poste 84577
|
(EN) A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence
EMBER-4
NCT05514054
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DU SAINT-SACREMENT
|
Sein |
Dre Brigitte Poirier
Fanie Bourgault
418-525-4444 poste 82697
|
(EN) A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole)+ CDK4/6 Inhibitor in HR+/HER2-MBC Patients With Detectable ESR1Mutation Without Disease Progression During 1L Treatment With Aromatase Inhibitor+ CDK4/6 Inhibitor- A ctDNA Guided Early Switch Study
SERENA-6
NCT04964934
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DU SAINT-SACREMENT
|
Sein |
Dre Catherine Doyle
Judith-Élise Marcoux
418-525-4444 poste 84577
|